PARP inhibitor counteracts Temozolomide Resistance in Glioblastoma Multiforme
Samarut, E.; Tabourel, G.; Briand, J.; Landais, Y.; Gratas, C.; Cartron, P.-F.; Vallette, F.; Oliver, L.; Serandour, A. A.
Show abstract
Glioblastoma multiforme (GBM), a highly aggressive brain tumor, frequently develops resistance to temozolomide (TMZ), the current standard chemotherapy. Our study investigates the potential of combining TMZ with the poly (ADP-ribose) polymerase inhibitor Olaparib (OLA) to overcome TMZ resistance. Using in vitro models, including U251 cell lines and patient-derived GBM primary cultures, we demonstrate that OLA enhances TMZ efficacy by disrupting base excision repair and potentiating DNA damage-induced cytotoxicity. A CRISPR knockout screen identified DNA mismatch repair (MMR) gene deficiencies as key drivers of TMZ resistance, which OLA effectively counteracts. Co-treatment with TMZ and OLA significantly reduced tumor cell viability, even in MMR-deficient and MGMT-expressing contexts, suggesting a synergistic mechanism. Gene expression analysis revealed that the combination therapy impacts cell cycle regulation, stress responses, and extracellular matrix integrity, leading to mitotic catastrophe and apoptosis. These findings propose the TMZ-OLA combination as a promising therapeutic strategy for overcoming chemoresistance in GBM.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Molecular Determinants of Calcitriol Signaling and Sensitivity in Glioma Stem-like Cells 95%
- Profiling anti-apoptotic protein BCL-xL expression in U-87 MG glioblastoma cells and patient-derived tumorspheres 94%
- Tyrosyl-DNA phosphodiesterase 1 and topoisomerase I activities as predictive indicators for Glioblastoma susceptibility to genotoxic agents 93%
Similar papers in this journal
- NOX4 regulates TGFβ-induced proliferation and self-renewal in glioblastoma stem cells. 94%
- CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds 92%
- Targeting LDHC dysregulates the cell cycle and improves sensitivity to cisplatin and olaparib 92%
Similar papers in this journal
Similar papers in this journal
- Virus-host protein-protein interactions between human papillomavirus 16 E6 A1 and D2/D3 sub-lineages: variances and similarities 92%
- Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries 92%
- Evolution of resistance to Irinotecan in cancer cells involves generation of topoisomerase-guided mutations in non-coding genome that reduce the chances of DNA breaks 92%
Similar papers in this journal
- Increasing Ciliary ARL13B Expression Drives Active and Inhibitor-Resistant SMO and GLI into Glioma Primary Cilia 91%
- NAD modulates DNA methylation and cell differentiation 91%
- RUNX1 is regulated by androgen receptor to promote cancer stem markers and chemotherapy resistance in triple negative breast cancer. 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.